Peripheral venous pressure changes during exercise are associated with adverse Fontan outcomes.

fontan physiology

Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
26 May 2021
Historique:
received: 17 06 2020
revised: 22 09 2020
accepted: 30 09 2020
medline: 1 11 2020
pubmed: 1 11 2020
entrez: 31 10 2020
Statut: epublish

Résumé

Elevated central venous pressure (CVP) plays an important role in the development of adverse Fontan outcomes. Peripheral venous pressure (PVP) has been validated as a surrogate for CVP in Fontan patients. We hypothesised that PVP in response to exercise will be associated with a greater prevalence of Fontan morbidity. Adult Fontan patients had cardiopulmonary exercise testing (CPET) with PVP monitoring in the upper extremity between 2015 and 2018. PVP at rest, during unloaded cycling and at peak exercise was compared between those with and without adverse Fontan outcomes including arrhythmia, unscheduled hospital admissions, heart failure requiring diuretics, need for reintervention and a composite outcome of the above morbidities, heart transplantation and death. Forty-six patients with a mean age at CPET of 26.9±9.5 years. During exercise, PVP increased from 13.6±3.5 mm Hg at rest, to 16.5±3.9 mm Hg during unloaded cycling, to 23.0±5.5 mm Hg at peak exercise. Unloaded and peak PVP were more strongly associated than resting PVP with all adverse outcomes, except reintervention (composite outcome: resting PVP: OR 2.8, p=0.023; unloaded PVP: OR 6.1, p=0.001; peak PVP: OR 4.0, p<0.001). Cut-offs determined using ROC curve analysis had high specificity for the composite outcome (88% unloaded PVP ≥18 mm Hg; 89% peak PVP ≥25 mm Hg). Higher PVP at unloaded and peak exercise was strongly associated with a higher prevalence of adverse Fontan outcomes. Minimally invasive PVP monitoring during CPET may serve as a useful tool for risk stratifying individuals with a Fontan.

Identifiants

pubmed: 33127650
pii: heartjnl-2020-317179
doi: 10.1136/heartjnl-2020-317179
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

983-988

Informations de copyright

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Kathleen Colman (K)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Tarek Alsaied (T)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Adam Lubert (A)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Harry B Rossiter (HB)

The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.

Wayne A Mays (WA)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Adam W Powell (AW)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Sandra Knecht (S)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Danielle Poe (D)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Nicholas Ollberding (N)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Zhiqian Gao (Z)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Clifford Chin (C)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Gruschen R Veldtman (GR)

Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA gruschen@me.com.

Classifications MeSH